Literature DB >> 26385306

Disorders of carnitine biosynthesis and transport.

Ayman W El-Hattab1, Fernando Scaglia2.   

Abstract

Carnitine is a hydrophilic quaternary amine that plays a number of essential roles in metabolism with the main function being the transport of long-chain fatty acids from the cytosol to the mitochondrial matrix for β-oxidation. Carnitine can be endogenously synthesized. However, only a small fraction of carnitine is obtained endogenously while the majority is obtained from diet, mainly animal products. Carnitine is not metabolized and is excreted in urine. Carnitine homeostasis is regulated by efficient renal reabsorption that maintains carnitine levels within the normal range despite variabilities in dietary intake. Diseases occurring due to primary defects in carnitine metabolism and homeostasis are comprised in two groups: disorders of carnitine biosynthesis and carnitine transport defect. While the hallmark of carnitine transport defect is profound carnitine depletion, disorders of carnitine biosynthesis do not cause carnitine deficiency due to the fact that both carnitine obtained from diet and efficient renal carnitine reabsorption can maintain normal carnitine levels with the absence of endogenously synthesized carnitine. Carnitine transport defect phenotype encompasses a broad clinical spectrum including metabolic decompensation in infancy, cardiomyopathy in childhood, fatigability in adulthood, or absence of symptoms. The phenotypes associated with the carnitine transport defect result from the unavailability of enough carnitine to perform its functions particularly in fatty acid β-oxidation. Carnitine biosynthetic defects have been recently described and the phenotypic consequences of these defects are still emerging. Although these defects do not result in carnitine deficiency, they still could be associated with pathological phenotypes due to excess or deficiency of intermediate metabolites in the carnitine biosynthetic pathway and potential carnitine deficiency in early stages of life when brain and other organs develop. In addition to these two groups of primary carnitine defects, several metabolic diseases and medical conditions can result in excessive carnitine loss leading to a secondary carnitine deficiency.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autism spectrum disorders; Cardiomyopathy; Carnitine transport defect; Fatty acid oxidation; Systemic carnitine deficiency

Mesh:

Substances:

Year:  2015        PMID: 26385306     DOI: 10.1016/j.ymgme.2015.09.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  33 in total

Review 1.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

Review 2.  L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Authors:  Gustavo C Ferreira; Mary C McKenna
Journal:  Neurochem Res       Date:  2017-05-16       Impact factor: 3.996

3.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Gani Bajraktari; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; Demosthenes B Panagiotakos; Gyorgy Paragh; Dimitri P Mikhailidis; Olena Mitchenko; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Kausik K Ray; Manfredi Rizzo; Amirhossein Sahebkar; Maria-Corina Serban; Laurence S Sperling; Peter P Toth; Dragos Vinereanu; Michal Vrablík; Nathan D Wong; Maciej Banach
Journal:  Arch Med Sci       Date:  2017-08-04       Impact factor: 3.318

4.  Liquid Chromatography-Mass Spectrometry-Based Metabolomics of Nonhuman Primates after 4 Gy Total Body Radiation Exposure: Global Effects and Targeted Panels.

Authors:  Evan L Pannkuk; Evagelia C Laiakis; Kirandeep Gill; Shreyans K Jain; Khyati Y Mehta; Denise Nishita; Kim Bujold; James Bakke; Janet Gahagen; Simon Authier; Polly Chang; Albert J Fornace
Journal:  J Proteome Res       Date:  2019-03-18       Impact factor: 4.466

Review 5.  Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.

Authors:  Adam J Kuszak; Michael Graham Espey; Marni J Falk; Marissa A Holmbeck; Giovanni Manfredi; Gerald S Shadel; Hilary J Vernon; Zarazuela Zolkipli-Cunningham
Journal:  Annu Rev Pathol       Date:  2017-11-03       Impact factor: 23.472

6.  Dilated Cardiomyopathy as the Only Clinical Manifestation of Carnitine Transporter Deficiency.

Authors:  Kyriaki Papadopoulou-Legbelou; Maria Gogou; Vaia Dokousli; Maria Eboriadou; Athanasios Evangeliou
Journal:  Indian J Pediatr       Date:  2016-11-03       Impact factor: 1.967

Review 7.  Carnitine Responsive Migraine Headache Syndrome: Case Report and Review of the Literature.

Authors:  Larry Charleston; Suad Khalil; William B Young
Journal:  Curr Pain Headache Rep       Date:  2021-03-23

8.  Infant with hepatomegaly and hypoglycemia: A setting for fatty acid oxidation defects.

Authors:  Aathira Ravindranath; Gautham Pai; Anshu Srivastava; Ujjal Poddar; Surender Kumar Yachha
Journal:  Indian J Gastroenterol       Date:  2017-10-26

9.  Sequence-Based Analysis of Lipid-Related Metabolites in a Multiethnic Study.

Authors:  Elena V Feofanova; Bing Yu; Ginger A Metcalf; Xiaoming Liu; Donna Muzny; Jennifer E Below; Lynne E Wagenknecht; Richard A Gibbs; Alanna C Morrison; Eric Boerwinkle
Journal:  Genetics       Date:  2018-04-02       Impact factor: 4.562

Review 10.  Carnitine transport and fatty acid oxidation.

Authors:  Nicola Longo; Marta Frigeni; Marzia Pasquali
Journal:  Biochim Biophys Acta       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.